<DOC>
	<DOCNO>NCT00153634</DOCNO>
	<brief_summary>This randomize multi-center clinical trial compare microbiological efficacy , clinical efficacy , safety use standard versus biofilm susceptibility test P. aeruginosa sputum isolate guide antibiotic selection treatment airway infection clinically stable patient CF .</brief_summary>
	<brief_title>Standard vs. Biofilm Susceptibility Testing Cystic Fibrosis ( CF )</brief_title>
	<detailed_description>Patients screen determine eligibility obtain sputum culture . Eligible patient randomize either standard biofilm study arm . Antibiotic selection perform centrally accord standard algorithm use susceptibility test result assign study arm . On Day 0 , patient start 14-day course two antibiotic select per protocol . Antibiotics administer intravenously ( IV ) and/or orally . A follow-up phone call visit occur Day 7 . An end treatment visit conduct completion antibiotic therapy . A total 39 patient randomize . Many screen patient ineligible randomization base microbiology result .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Ticarcillin-clavulanic acid</mesh_term>
	<mesh_term>Ticarcillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Diagnosis CF base following : sweat chloride &gt; 60 mEq/L ( quantitative pilocarpine iontophoresis ) , genotype 2 identifiable mutation consistent CF ; one clinical feature consistent CF . Age ≥ 14 year ( change ≥ 18 year protocol amendment ) . Able expectorate sputum screening . History persistent positivity P. aeruginosa respiratory culture ( least three positive oropharyngeal ( OP ) , sputum and/or bronchoscopy culture 24 month prior screen ) . Able reproducibly perform pulmonary function test . Clinically stable screening , evidence pulmonary exacerbation . Written inform consent provide . Sputum culture negative P. aeruginosa density le 10E5 CFU/gm screening . Sputum culture positive B. cepacia screening . Presence P. aeruginosa sputum offscale resistance antibiotic either method susceptibility test screening . ( change multiplyresistant P. aeruginosa protocol amendment ) History B. cepacia positive respiratory culture within 24 month prior screen . Hospitalization treatment pulmonary exacerbation within 2 month prior screen . Administration parenteral antipseudomonal antibiotic within 2 month prior screen . Treatment oral inhale antipseudomonal antibiotic , azithromycin macrolides within 14 day prior screen . History allergy ( urticarial rash , diffuse erythroderma , serum sickness ) two group antibiotic ( aminoglycosides , penicillin , cephalosporin , monobactams , macrolides , quinolones ) therapeutic option . History anaphylaxis life threaten complication antibiotic six group therapeutic option . History abnormal renal function ( serum creatinine &gt; 1.5 x upper limit normal ) within one year enrollment . History abnormal liver function test ( &gt; 2.5 x upper limit normal ) within one year enrollment . Clinically documented hearing loss precludes treatment aminoglycosides . Post lung transplantation . Positive pregnancy test female lactate practice acceptable method birth control . Presence condition abnormality opinion investigator would compromise safety patient quality data . Administration investigational agent within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Antibiotic susceptibility test</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>Chronic bronchitis</keyword>
	<keyword>Biofilms</keyword>
</DOC>